BenevolentAI
subject to positive date the asset will then be ready for phase i studies in poised for growth multiple value in points ben data expected ben out licensing internal pipeline depth and progression ben begin phase i study ben submit clinical trial application expect to add names drug programmes to portfolio ben phase i data package phase to follow shortly after ben initiate phase i study collaboration other platform collaborations aim to progress stage drug candidates every year potential new targets added for and heart failure prior targets for and for advancing discussions with a number of parties ongoing inflection | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
28 of 38
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
January 2023
poised for growth multiple value in points inflection | BenevolentAI
Investor Conference
November 2022
multiple value in points expected ben atopic dermatitis ben ulcerative colitis ben ben amyotrophic lateral sclerosis pipeline depth and progression collaboration other platform collaborations inflection | BenevolentAI
Investor Presentation
October 2022
portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI
Investor Day
September 2022
portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI
Related slides by other companies
Anebulo Pharmaceuticals
Investor Day
September 2022
phase and observational study data for modeling | Anebulo Pharmaceuticals
Compass Therapeutics
Investor Presentation
May 2022
phase combination study status | Compass Therapeutics
NeuroSense Therapeutics
Investor Presentation
October 2024
phase a data demonstrated reduced and levels in als patients treated with | NeuroSense Therapeutics
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase studies well tolerated with no dose dependent adverse events in sad and mad mad study placebo further confidence confirming safety | Recursion Pharmaceuticals
Other recent decks by BenevolentAI
See all presentations (11 decks)
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights